Evidence map›Paper›PMID 20981448›Full record

ArticleHuman genetics2011

A novel survival multifactor dimensionality reduction method for detecting gene-gene interactions with application to bladder cancer prognosis.

Jiang Gui, Jason H Moore, Karl T Kelsey, Carmen J Marsit, Margaret R Karagas, Angeline S Andrew

Abstract readEvaluation Study
In one paragraph

Article in Human genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Overview of frequent pattern mining.Genomics & informatics · 2022
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Gene-gene interaction: the curse of dimensionality.Annals of translational medicine · 2019
    Review
  13. Robust genetic interaction analysis.Briefings in bioinformatics · 2019
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiang GuiDepartment of Community and Family Medicine, Norris-Cotton Cancer Center, Dartmouth Medical School, One Medical Center Drive, Lebanon, NH 03756, USA.
Jason H Moore
Karl T Kelsey
Carmen J Marsit
Margaret R Karagas
Angeline S Andrew

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
VARIATION IN BIOACCUMULATION AND BIOMAGNIFICATION OF METALS IN NORTHERN US LAKESP42ES007373 · NIEHS · DARTMOUTH COLLEGE · PI STANTON, BRUCE A. · 1995 to 2019
$52.0M
NONMELANOMA SKIN CANCER IN NEW HAMPSHIRER01CA057494 · NCI · DARTMOUTH COLLEGE · PI KARAGAS, MARGARET RITA · 1993 to 2015
$10.9M
Quantitative Biology Research InstituteP20GM103534 · NIGMS · DARTMOUTH COLLEGE · PI AMOS, CHRISTOPHER I. · 2012 to 2016
$8.6M
The Boston Collaborative Oral Cancer StudyR01CA078609 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI KELSEY, KARL TIMOTHY · 1999 to 2010
$5.3M
Bioinformatics Strategies for Genome-Wide Association StudiesR01LM010098 · NLM · UNIVERSITY OF PENNSYLVANIA · PI MOORE, JASON H., WILLIAMS, SCOTT MATTHEW · 2009 to 2023
$5.1M
Bioinformatics Strategies: Biodefense Vaccine ResearchR01AI059694 · NIAID · DARTMOUTH COLLEGE · PI MOORE, JASON H. · 2004 to 2012
$4.5M
Machine Learning Prediction of Cancer SusceptibilityR01LM009012 · NLM · UNIVERSITY OF PENNSYLVANIA · PI MOORE, JASON H. · 2006 to 2014
$3.3M
QUANTITATIVE BIOLOGY RESEARCH INSTITUTEP20RR024475 · NCRR · DARTMOUTH COLLEGE · PI MOORE, JASON H. · 2011 to 2011
$2.3M
Bladder Cancer Prognostic IndicatorsK07CA102327 · NCI · DARTMOUTH COLLEGE · PI ANDREW, ANGELINE SANDERSON · 2005 to 2009
$819k
Comprehensive Assessment of Bladder Cancer Genetic SusceptibilityR03CA121382 · NCI · DARTMOUTH COLLEGE · PI ANDREW, ANGELINE SANDERSON · 2006 to 2007
$158k
NCI NIH HHS CA078609NCI NIH HHS CA102327NCI NIH HHS CA121382NCI NIH HHS CA57494NCI NIH HHS K07 CA102327NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA057494NCI NIH HHS R01 CA078609NCI NIH HHS R03 CA121382NCRR NIH HHS P20 RR024475NIAID NIH HHS AI59694NIAID NIH HHS R01 AI059694NIEHS NIH HHS ES007373NIEHS NIH HHS P42 ES007373NIGMS NIH HHS P20 GM103534NLM NIH HHS LM009012NLM NIH HHS LM010098NLM NIH HHS R01 LM009012NLM NIH HHS R01 LM010098
6 · The paper itself

Abstract

The widespread use of high-throughput methods of single nucleotide polymorphism (SNP) genotyping has created a number of computational and statistical challenges. The problem of identifying SNP-SNP interactions in case-control studies has been studied extensively, and a number of new techniques have been developed. Little progress has been made, however, in the analysis of SNP-SNP interactions in relation to time-to-event data, such as patient survival time or time to cancer relapse. We present an extension of the two class multifactor dimensionality reduction (MDR) algorithm that enables detection and characterization of epistatic SNP-SNP interactions in the context of survival analysis. The proposed Survival MDR (Surv-MDR) method handles survival data by modifying MDR's constructive induction algorithm to use the log-rank test. Surv-MDR replaces balanced accuracy with log-rank test statistics as the score to determine the best models. We simulated datasets with a survival outcome related to two loci in the absence of any marginal effects. We compared Surv-MDR with Cox-regression for their ability to identify the true predictive loci in these simulated data. We also used this simulation to construct the empirical distribution of Surv-MDR's testing score. We then applied Surv-MDR to genetic data from a population-based epidemiologic study to find prognostic markers of survival time following a bladder cancer diagnosis. We identified several two-loci SNP combinations that have strong associations with patients' survival outcome. Surv-MDR is capable of detecting interaction models with weak main effects. These epistatic models tend to be dropped by traditional Cox regression approaches to evaluating interactions. With improved efficiency to handle genome wide datasets, Surv-MDR will play an important role in a research strategy that embraces the complexity of the genotype-phenotype mapping relationship since epistatic interactions are an important component of the genetic basis of disease.

Indexed as

Epistasis, GeneticPolymorphism, Single NucleotideAdultAgedAlgorithmsCase-Control StudiesComputer SimulationFollow-Up StudiesGenetic LociHumansMiddle AgedModels, GeneticMultifactor Dimensionality ReductionNew HampshirePrognosisSurvival Analysis

Identifiers

PMID20981448
PMCPMC3255326

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.